Asosiy kontentga oʻtish
AkademIndex

Xizmatlar

← Ishga qaytish

Ushbu ish iqtibos qilgan ishlar

21 ta ish

Ish: Social network-based ethical analysis of COVID-19 vaccine supply policy in three Central Asian countries

  1. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

    Fernando P. Polack, Stephen J. Thomas, Nicholas Kitchin +26

    Maqola20208 iqtibos
    ABI

  2. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

    Denis Y. Logunov, Inna V. Dolzhikova, Dmitry V. Shcheblyakov +28

    Maqola20216 iqtibos
    ABI

  3. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis

    Derek K. Chu, Elie A Akl, Stephanie Duda +39

    Sharh maqola20204 iqtibos
    ABI

  4. Recombinant vaccines for COVID-19

    Tushar Yadav, Nishant Srivastava, Gourav Mishra +4

    Sharh maqola20203 iqtibos
    ABI

  5. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

    Merryn Voysey, Sue Ann Costa Clemens, Shabir A. Madhi +97

    Maqola20203 iqtibos
    ABI

  6. International Ethical Guidelines for Health-related Research involving Humans

    Council for International Organizations of Medical Sciences (CIOMS)

    Hisobot20163 iqtibos
    ABI

  7. The ethics of ‘public understanding of ethics’—why and how bioethics expertise should include public and patients’ voices

    Silke Schicktanz, Mark Schweda, Brian Wynne

    Maqola20112 iqtibos
    ABI

  8. Opinion summarization methods: Comparing and extending extractive and abstractive approaches

    Roque López, Thiago Alexandre Salgueiro Pardo

    Maqola20172 iqtibos
    ABI

  9. Vaccine Efficacy Needed for a COVID-19 Coronavirus Vaccine to Prevent or Stop an Epidemic as the Sole Intervention

    Sarah M. Bartsch, Kelly J. O’Shea, Marie C. Ferguson +8

    Maqola20202 iqtibos
    ABI

  10. Good reasons to vaccinate: mandatory or payment for risk?

    Julian Savulescu

    Maqola20202 iqtibos
    ABI

  11. COVID-19 response in central Asia

    Vijay Shankar Balakrishnan

    Maqola20202 iqtibos
    ABI

  12. Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination

    Roy M. Anderson, Carolin Vegvari, James E. Truscott +1

    Maqola20202 iqtibos
    ABI

  13. Ethical allocation of future COVID-19 vaccines

    Rohit Gupta, Stephanie R. Morain

    Maqola20202 iqtibos
    ABI

  14. COVID-19 mortality risk assessment: An international multi-center study

    Dimitris Bertsimas, Galit Lukin, Luca Mingardi +16

    Maqola20202 iqtibos
    ABI

  15. Covax must go beyond proportional allocation of covid vaccines to ensure fair and equitable access

    Lisa Herzog, Ole Frithjof Norheim, Ezekiel Emanuel +1

    Maqola20212 iqtibos
    ABI

  16. Just allocation of COVID-19 vaccines

    Anders Herlitz, Zohar Lederman, Jennifer Miller +5

    Maqola20212 iqtibos
    ABI

  17. Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment

    Olivier J. Wouters, Kenneth C. Shadlen, Maximilian Salcher‐Konrad +4

    Sharh maqola20212 iqtibos
    ABI

  18. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study

    Robert Challen, Ellen Brooks‐Pollock, Jonathan M. Read +3

    Maqola20212 iqtibos
    ABI

  19. WHO’s allocation framework for COVAX: is it fair?

    Siddhanth Sharma, Nisrine Kawa, Apoorva Gomber

    Maqola20212 iqtibos
    ABI

  20. How long does covid-19 immunity last?

    Chris Baraniuk

    Maqola20212 iqtibos
    ABI

  21. Sarlavhasiz

    Boshqa1 iqtibos
    ABI